Competition Pharmaceutical Pharmaceutical manufacturing Safety 
European Pharmaceutical Review
DECEMBER 4, 2023
The (bio)pharmaceutical industry is currently facing numerous hurdles in its path to high-efficiency production that are more complex and pressing than ever before. Simultaneously, there is increasing need for stringent quality control and traceability throughout the supply chain to ensure patient safety. principles.
European Pharmaceutical Review
APRIL 11, 2024
The pharmaceutical industry is becoming increasingly conscious of emissions and the importance of sustainable manufacturing. Globally, the pharmaceutical sector emitted around 52 megatonnes of CO 2 in 2015, the most recent period for which detailed numbers are available. References Belkhir L, Elmeligi A.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
World of DTC Marketing
APRIL 12, 2021
We need a 21st-century approach that puts patient safety first. The US Food and Drug Administration (FDA) believes the adulteration of heparin was an economically motivated act—a clear breach of the US pharmaceutical supply chain. In other words, money over safety. Up to 90% of drugs now sold in the US and UK are generic.
Contrarian Sales Techniques
FEBRUARY 26, 2023
The paper was presented at the International Conference on Pharmaceutical Research and Development (IPRDC) in Kuala Lumpur, Malaysia, in June 2017. It is noteworthy that Malaysia has a pharmaceutical manufacturing sector that almost exclusively produces generic drugs, with sales revenues amounting to only 1.5%
PM360
APRIL 25, 2023
Although AbbVie’s patent for Humira officially expired in 2016, the legal and regulatory delays paused competition for Humira until 2023. pharmaceutical industry. Financial incentives were explored further in the survey as biosimilars are expected to increase competition, thereby lower cost and increase access.
pharmaphorum
NOVEMBER 25, 2022
Having a healthy and sustainable pharmaceutical sector is both a necessary requirement and a good one for society. Alberto Chiesi deemed Italian pharmaceutical industries the “reference leaders in Europe”. Going beyond the standards of care; improving drug safety and efficacy.
European Pharmaceutical Review
NOVEMBER 8, 2022
3) policing anticompetitive settlements between competing drug manufacturers. European pharmaceutical companies targeting the US market should be aware of these pending bills and their potential impacts on market entry, intellectual property enforcement and payer access. 5) monitoring access to biosimilars.
Expert insights. Personalized for you.
91 
Let's personalize your content